Cost-Effectiveness Analysis of HIV/AIDS Programme for Policy Decision in Nigeria: An Appraisal of Evidence Using the Drummond Checklist

Henry Omoregie Egharevba

National Institute for Pharmaceutical Research and Development (Nigeria)

Amidst declining access to funding, the HIV/AIDS pandemic remains a confounding health issue in sub-Saharan countries, especially Nigeria. The selection and sustainability of numerous programmes aimed at encouraging and upscaling uptake and adherence to intervention have become more critical. Hence, the assessment of evidence on the economic evaluation of programmes’ effectiveness to inform decisions on scale-up has become inevitable. While several approaches to valuation exist, cost-effectiveness analysis (CEA) is widely used by many researchers. In this study, an evaluation of research evidence on the cost-effectiveness analysis of a HIV/AIDS programme was undertaken. The weaknesses, and the need to incorporate other considerations, such as long-term utility cost measures (QALYs/DALYs) and forecast, as well as equity, diversity and inclusion, were discussed using the Drummond 10-question checklist. The author recommends the use or inclusion of a cost-utility analysis (CUA) or cost-benefit analysis (CBA) in the economic valuation of HIV/AIDS programmes for policy decision-making in Nigeria

Article link: https://www.asianinstituteofresearch.org/JHMSarchives/cost-effectiveness-analysis-of-hiv%2Faids-programme-for-policy-decision-in-nigeria%3A-an-appraisal-of-evidence-using-the-drummond-checklist-